Edition:
India

Cardiovascular Systems Inc (CSII.OQ)

CSII.OQ on NASDAQ Stock Exchange Global Select Market

38.93USD
10:39pm IST
Change (% chg)

$0.91 (+2.39%)
Prev Close
$38.02
Open
$38.41
Day's High
$39.14
Day's Low
$38.02
Volume
22,795
Avg. Vol
131,106
52-wk High
$55.15
52-wk Low
$26.00

Latest Key Developments (Source: Significant Developments)

Cardiovascular Systems Reports Fiscal 2020 Third-Quarter Financial Results
Wednesday, 6 May 2020 

May 5 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 THIRD-QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.08.Q3 REVENUE $61.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $65.8 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.CREDIT FACILITY INCREASED TO $50 MILLION AND EXTENDED TO MARCH 2022.CSI WITHDREW FISCAL 2020 GUIDANCE.TAKEN ACTIONS TO REDUCE OUR VARIABLE SPENDING.  Full Article

Cardiovascular Systems Enteres Amendment To Loan And Security Agreement Dated March 31, 2017
Friday, 27 Mar 2020 

March 26 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS INC - ENTERED INTO FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED MARCH 31, 2017.CARDIOVASCULAR SYSTEMS INC - AMENDMENT EXTENDS MATURITY DATE OF LOAN AGREEMENT BY TWO YEARS, TO MARCH 31, 2022.CARDIOVASCULAR SYSTEMS - AMENDMENT INCREASES MAXIMUM AMOUNT AVAILABLE UNDER REVOLVING CREDIT FACILITY UNDER LOAN AGREEMENT FROM $40.0 MILLION TO $50.0 MILLION.  Full Article

Cardiovascular Systems Entered Into Amendment No. 2 To Supply Agreement & Amendment No. 2 To Product Schedule With Fresenius Kabi AB
Friday, 20 Mar 2020 

March 20 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS - ENTERED INTO AMENDMENT NO. 2 TO SUPPLY AGREEMENT & AMENDMENT NO. 2 TO PRODUCT SCHEDULE WITH FRESENIUS KABI AB.CARDIOVASCULAR SYSTEMS INC - SUPPLY AMENDMENT PRIMARILY EXTENDS TERM OF SUPPLY AGREEMENT FOR AN ADDITIONAL FORTY-FOUR MONTHS, TO DECEMBER 31, 2024.CARDIOVASCULAR SYSTEMS INC - PRODUCT SCHEDULE AMENDMENT PRIMARILY UPDATES PRODUCT PRICING SCHEDULE AND RELATED TERMS.CARDIOVASCULAR SYSTEMS INC - COMPANY IS EXPERIENCING AND MAY EXPERIENCE OTHER DISRUPTIONS AS A RESULT OF COVID-19 OUTBREAK.  Full Article

Cardiovascular Systems Reports Q2 Loss Per Share $0.10
Thursday, 6 Feb 2020 

Feb 5 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 SECOND-QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.10.Q2 REVENUE $68.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $68 MILLION.SEES FY 2020 REVENUE $280 MILLION TO $283 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.01 -- REFINITIV IBES DATA.COMPANY RAISES LOW END OF FISCAL 2020 REVENUE GUIDANCE RANGE.SEES FY 2020 REVENUE OF $280 MILLION TO $283 MILLION, REPRESENTING 13% TO 14% GROWTH COMPARED WITH FISCAL 2019.SEES FY 2020 POSITIVE ADJUSTED EBITDA.FY2020 EARNINGS PER SHARE VIEW $-0.03, REVENUE VIEW $280.7 MILLION -- REFINITIV IBES DATA.  Full Article

Cardiovascular Systems Posts Q1 Loss Of $0.17/Share
Wednesday, 30 Oct 2019 

Oct 29 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 FIRST-QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.17.Q1 REVENUE $64.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $63.9 MILLION.SEES FY 2020 REVENUE UP 12 TO 14 PERCENT.SEES FY 2020 REVENUE $278 MILLION TO $283 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.REITERATES FISCAL 2020 FINANCIAL GUIDANCE.  Full Article

Cardiovascular Systems Q4 Earnings Per Share $0.04
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 FOURTH-QUARTER FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.04.Q4 REVENUE $68.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $66.1 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.04 -- REFINITIV IBES DATA.SEES FY 2020 REVENUE UP 12 TO 14 PERCENT.SEES FY 2020 REVENUE $278 MILLION TO $283 MILLION.COMPANY INTRODUCES FISCAL 2020 FINANCIAL GUIDANCE.  Full Article

Cardiovascular Systems Q3 Earnings Per Share $0.02
Thursday, 2 May 2019 

May 1 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 THIRD-QUARTER FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.02.Q3 REVENUE $63.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $62.8 MILLION.SEES FY 2019 REVENUE UP 13 TO 14 PERCENT.SEES FY 2019 REVENUE $245 MILLION TO $247 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.INCREASES FISCAL 2019 REVENUE GUIDANCE TO UPPER HALF OF PREVIOUS RANGE.  Full Article

Cardiovascular Systems Reports Q2 EPS Of $0.01
Thursday, 31 Jan 2019 

Jan 30 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 SECOND-QUARTER FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.01.Q2 REVENUE $60.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $59.7 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.04 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $243 MILLION TO $247 MILLION."REMAIN ON TRACK TO ACHIEVE MIDPOINT OF OUR FISCAL 2019 REVENUE GUIDANCE RANGE".SEES FISCAL 2019 NET LOSS EQUAL TO 1%-2% OF REVENUE.SEES POSITIVE ADJUSTED EBITDA FOR FISCAL 2019.  Full Article

Cardiovascular Systems, Aerolase Corp To Collaborate On Laser Atherectomy Technology
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Cardiovascular Systems Inc ::CARDIOVASCULAR SYSTEMS, INC. AND AEROLASE CORP. SIGN COLLABORATIVE AGREEMENT FOR LASER ATHERECTOMY TECHNOLOGY.CARDIOVASCULAR SYSTEMS INC - UNDER TERMS OF AGREEMENT, CSI MADE AN UNDISCLOSED EQUITY INVESTMENT IN AEROLASE.CARDIOVASCULAR SYSTEMS INC - CSI WILL MAKE ADDITIONAL EQUITY INVESTMENTS IN AEROLASE AS DEVELOPMENT MILESTONES ARE MET.  Full Article